(R)-Simurosertib

CAS No. 1330782-69-8

(R)-Simurosertib( —— )

Catalog No. M33092 CAS No. 1330782-69-8

(R)-Simurosertib ((R)-TAK-931) is an ATP-competitive inhibitor of the cell division cycle 7 (CDC7) kinase.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 67 In Stock
2MG 28 In Stock
5MG 46 In Stock
10MG 73 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (R)-Simurosertib
  • Note
    Research use only, not for human use.
  • Brief Description
    (R)-Simurosertib ((R)-TAK-931) is an ATP-competitive inhibitor of the cell division cycle 7 (CDC7) kinase.
  • Description
    (R)-Simurosertib ((R)-TAK-931) is the (R)-enantiomer of Simurosertib. Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1330782-69-8
  • Formula Weight
    341.43
  • Molecular Formula
    C17H19N5OS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 75 mg/mL (219.66 mM; Ultrasonic )
  • SMILES
    Cc1n[nH]cc1-c1cc2nc([nH]c(=O)c2s1)[C@H]1CC2CCN1CC2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. K Iwai, et al. A novel CDC7-selective inhibitor TAK-931 with potent antitumor activity. European Journal of Cancer , 2016 , 69 (1) :S34.
molnova catalog
related products
  • Cdc7-IN-7

    Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.

  • (R)-Enitociclib

    (R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.

  • Riviciclib

    A novel potent CDK inhibitor with IC50 of 79 nM, 63 nM and 20 nM for Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, respectively.